CLS Americas and HALO Precision Diagnostics Announce 25 Patient Post-Market Study to Evaluate CLS’s TRANBERG Thermal Therapy System

IRVINE, Calif. and INDIAN WELLS, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) — Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO Precision Diagnostics, Inc. (HALO), today announced a Letter of Intent to evaluate the safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy System for treating low-to-medium risk prostate cancer patients with FLA therapy outside of a hospital setting. HALO will conduct an initial post-market study treating up to twenty-five (25) patients at one or more of its HALO Ambulatory Surgery Centers. Upon completion of its evaluation, HALO and CLS will enter into discussions regarding HALO’s acquisition of the CLS TRANBERG Laser System for use in some of its nationwide system of approximately 16 clinics.